Continuing Medical Education Program – Purchase Activities

Continuing Medical Education Program – Purchase Activities

The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

   The Medical Letter Individual Activities — Online Only
I would like to order the following Per Issue Activities eligible for 2 credits each: $15 per activity
3 or more: $10/activity
1648 (2 credits)  Expires 04/06/2023
In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance)
Tramadol/Celecoxib (Seglentis) for Pain
A Drug-Eluting Contact Lens for Allergic Conjunctivitis
Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose
Efgartigimod alfa (Vyvgart) for Myasthenia Gravis
1649 (2 credits)  Expires 04/20/2023
Drugs for Benign Prostatic Hyperplasia
Vazalore - A New Aspirin Formulation
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
1650 (2 credits)
A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis
Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
1651 (2 credits)
Drugs and Devices for Weight Management
1652 (2 credits)
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
1653 (2 credits)
Drugs for Sexually Transmitted Infections
1654 (2 credits)
Tirzepatide (Mounjaro) for Type 2 Diabetes
Daridorexant (Quviviq) for Insomnia
COVID-19 Updates
1655 (2 credits)
Drugs for Treatment and Prevention of Venous Thromboembolism
1656 (2 credits)
COVID-19 Updates
Tapinarof Cream (Vtama) for Psoriasis
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
Lumateperone (Caplyta) for Bipolar Depression
1657 (2 credits)
Drugs for Cognitive Loss and Dementia
1658 (2 credits)
Prevention and Treatment of Monkeypox
Baricitinib (Olumiant) for Severe Alopecia Areata
Nalmefene Returns for Reversal of Opioid Overdose
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
1659 (2 credits)
Lipid-Lowering Drugs
1660 (2 credits)
Influenza Vaccine for 2022-2023
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
COVID-19 Update
1661 (2 credits)
Adult Immunization
1662 (2 credits)
Two Vonoprazan Combinations (Voquezna) for H. pylori
Two New Oral Testosterone Products for Hypogonadism
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
OTC Azelastine Nasal Spray 0.15% (Astepro Allergy) for Allergic Rhinitis
1663 (2 credits)
Drugs for Type 2 Diabetes
1664 (2 credits)
Antiviral Drugs for Influenza for 2022-2023
Relyvrio for ALS
Alternatives to Adderall
1665 (2 credits)
Opioids for Pain
1666 (2 credits)
Dextromethorphan/Bupropion (Auvelity) for Depression
Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
Oral Minoxidil for Hair Loss
1667 (2 credits)
Drugs for Chronic Insomnia
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
1668 (2 credits)
Hemgenix - A Gene Therapy for Hemophilia B
Topical Roflumilast (Zoryve) for Plaque Psoriasis
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure
Finerenone (Kerendia) for Diabetic Kidney Disease
1669 (2 credits)
Lecanemab (Leqembi) for Alzheimer's Disease
Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
Epsolay - A Benzoyl Peroxide Cream for Rosacea
Transdermal Dextroamphetamine (Xelstrym) for ADHD
1670 (2 credits)
Drugs for Hypothyroidism
Deucravacitinib (Sotyktu) for Plaque Psoriasis
Expanded Access to Mifepristone
Semaglutide (Wegovy) for Weight Loss in Children
1671 (2 credits)
Antiviral Drugs for COVID-19 in Vaccinated Outpatients
Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer
1672 (2 credits)
Drugs for Overactive Bladder
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis
Terlipressin (Terlivaz) for Hepatorenal Syndrome
Off-Label Amitriptyline for Insomnia
1673 (2 credits)
Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration
Three Drugs for Atopic Dermatitis


ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

AAFP The AAFP has reviewed The Medical Letter Continuing Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2023 to 12/31/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hours of knowledge-based continuing education credit (0.2 CEU).